Articles

• Zucca E, Ceriani L, Ciccone G, Di Rocco A, Pirosa MC, Kriachok I, Botto B, Balzarotti M MD, Tucci A, Usai SV, Zilioli VR, Pennese E, Arcaini L, Dabrowska-Iwanicka AP, Ferreri AJM, Merli F, Zhao WL, Rigacci L, Cellini C, Hodgson D, Ionescu C, Minoia C, Lucchini E, Spina M, Fosså A, Janikova A, Cwynarski K, Mikhaeel NG, Jerkeman M, Stathis A, Cozens KS, Ielmini N, De Martino I, Walewski J, Trněný M, Cavalli F, Ricardi U, Johnson PWM, Davies AJ, Martelli M. Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial. Blood. 2025 Sep 12:blood.2025028823. doi: 10.1182/blood.2025028823. Epub ahead of print. PMID: 40939190.
• Vodicka P, Janikova A, Belada D, Hanackova V, Mocikova H, Duras J, Steinerova K, Benesova K, Konirova E, Prochazka T, Polgarova K, Masar M, Dlouha J, Blahovcova P, Trneny M. Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results. Hematol Oncol. 2025 Nov;43(6):e70142. doi: 10.1002/hon.70142. PMID: 41108618; PMCID: PMC12535275.
• Obr A, Malarikova D, Kriegova E, Urbankova H, Zemanova Z, Manakova J, Petrackova A, Vatolikova M, Berkova A, Forsterova K, Furst T, Hruskova A, Flodr P, Hanackova V, Prochazka V, Papajik T, Trneny M, Klener P. Fundamental prognostic difference of ATM gene mutation and deletion in newly diagnosed mantle cell lymphoma. Mol Med. 2025 Sep 29;31(1):306. doi: 10.1186/s10020-025-01376-2. PMID: 41023839; PMCID: PMC12481964.
• Mocikova H, Janikova A, Sykorova A, Prochazka V, Pirnos J, Duras J, Kopeckova K, Steinerova K, Pytlik R, Blahovcova P, Salek D, Kozak T, Bachanova V, Belada D. Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data. Ann Hematol. 2025 Jan;104(1):675-684. doi: 10.1007/s00277-024-06025-y. Epub 2024 Oct 1. PMID: 39352469; PMCID: PMC11868350.
• Klanova M, Hricko S, Masar M, Vodicka P, Salek D, Kopalova N, Blahovcova P, Kuruczova D, Benesova K, Michalka J, Koren J, Klener P, Janikova A, Trneny M. Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on? Hemasphere. 2025 Sep 9;9(9):e70201. doi: 10.1002/hem3.70201. PMID: 40933274; PMCID: PMC12417966.
• Hanáčková V, Polgárová K, Henzlová L, Zogala D, Obr A, Trněný M, Papajík T, Procházka V. Enhancing prognostic accuracy in PMBCL: semiquantitative analysis of interim PET/CT scans. Sci Rep. 2025 Oct 7;15(1):34898. doi: 10.1038/s41598-025-18649-9. PMID: 41057401; PMCID: PMC12504648.
• Conconi A, Janikova A, Vannata B, Ramírez-Ibarguen AF, Lobetti-Bodoni C, Belada D, Pirosa MC, Mian M, Ferreri AJM, Ryan G, Pangalis G, Cabrera ME, Luminari S, Montoto S, Tsang R, Aurer I, Visco C, Casaluci GM, Prochazka V, Hricko S, Stathis A, Mazzucchelli L, Ponzoni M, Federico M, Gaidano G, Lopez-Guillermo A, Pro B, Rossi D, Cascione L, Nowakowsky G, Trneny M, Zucca E. Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG). Hematol Oncol. 2025 Jul;43(4):e70111. doi: 10.1002/hon.70111. PMID: 40544479.

ASH abstracts

• Vodicka P, Wang Y, Benesova K, Reagan P, Salek D, Lossos IS, Prochazka V, Koff J, Sykorova A, Mou E, Mocikova H, Feldman A, Prouzova Z, Kahl B, Ďuraš J, Tsang M, Steinerova K, Nze C, Malarikova D, Mwangi R, Janikova A, Khurana A, Galko J, Martin P, Polgarova K, Syrbu S, Koren J, Obr A, Friedberg J, Belada D, Kascak M, Cohen J, Masar M, Suri A, Nowakowski G, Hricko S, Hrušková A, Flowers C, Bergerova V, Blahovcova P, Maurer M, Michalka J, Campr V, Habermann T, Klener P, Cerhan J, Trneny M. Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts. Blood. 2025;146:786.
• Vodicka P, Salek D, Benesova K, Belada D, Mocikova H, Hanackova V, Ďuraš J, Steinerova K, Salkova J, Prouzova Z, Pirnos J, Janikova A, Sykorova A, Suri A, Koren J, Galko J, Michalka J, Dlouha J, Blahovcova P, Campr V, Klener P, Trneny M. Bulky disease and/or very high LDH define a high-risk LBCL subgroup within IPI 1–2, but only in younger patients. Blood. 2025;146:470.
• Vodicka P, Reagan P, Masar M, Lossos IS, Benesova K, Mou E, Polgarova K, Jaye D, Malarikova D, Nze C, Koren J, Patel D, Karban J, Martin P, Salkova J, Feldman A, Dlouha J, Cohen J, Blahovcova P, Mwangi R, Habermann T, Jaksa R, Maurer M, Klanova M, Nowakowski G, Klener P, Friedberg J, Flowers C, Trneny M, Cerhan J. Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP. Blood. 2025;146:5448.
• Masar M, Vodicka P, Hricko S, Sykorova A, Hrušková A, Ďuraš J, Suri A, Bergerová V, Pirnos J, Lukac A, Benesova K, Filipova M, Belada D, Prochazka V, Kascak M, Mocikova H, Steinerova K, Koren J, Janikova A, Stepankova P, Obr A, Gerykova M, Klener P, Salek D, Michalka J, Dlouha J, Blahovcova P, Galko J, Campr V, Klanova M, Trneny M. Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort. Blood. 2025;146:3676.
• Kascak M, Vodicka P, Mensikova K, Martin S, Adam Z, Salek D, Janikova A, Karban J, Salkova J, Spacek M, Belada D, Sykorova A, Simkovic M, Stepankova P, Radocha J, Jungova A, Dekojova T, Jindra P, Steinerova K, Prochazka T, Jelinek T, Žihala D, Ďuraš J, Prochazka V, Obr A, Hanackova V, Minarik J, Heindorfer A, Klcova J, Mocikova H, Soukup J, Sykora M, Kessler P, Schulzova R, Wrobel M, Stejskal L, Mikula P, Campr V, Dlouha J, Blahovcova P, Kovacova I, Pour L, Trneny M, Hajek R. Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data. Blood. 2025;146:1834.
• Vodicka P, Maurer M, Masar M, Wang Y, Janikova A, Lossos IS, Belada D, Cohen J, Obr A, Mou E, Mocikova H, Casulo C, Ďuraš J, Nze C, Steinerova K, Patel D, Karban J, Martin P, Salek D, Feldman A, Sykorova A, Cahn E, Klanova M, Campr V, Jaye D, Michalka J, Stepankova P, Syrbu S, Hricko S, Suri A, Larson M, Jaksa R, Dlouha J, Habermann T, Blahovcova P, Flowers C, Klener P, Prochazka V, Cerhan J, Trneny M. FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis. Blood. 2025;146:1826.
• Vodicka P, Maurer M, Klener P, Cholack G, Prochazka V, Wang Y, Belada D, Flowers C, Salek D, Lossos IS, Mocikova H, Feldman A, Ďuraš J, Cohen J, Steinerova K, Casulo C, Pirnos J, Kahl B, Polgarova K, Mou E, Janikova A, Martin P, Sykorova A, Obr A, Jaye D, Campr V, Malarikova D, Riska S, Kascak M, Suri A, Nze C, Michalka J, Jaksa R, Nowakowski G, Dlouha J, Blahovcova P, Habermann T, Benesova K, Cerhan J, Trneny M. Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma. Blood. 2025;146:4516.
• Vodicka P, Masar M, Thompson C, Benesova K, Lossos IS, Malarikova D, Williams A, Polgarova K, Nze C, Koren J, Cohen J, Salkova J, Feldman A, Karban J, Mou E, Kovarikova P, Cahn E, Konirova E, Martin P, Dlouha J, Tsang M, Patel D, Blahovcova P, Reagan P, Jaye D, Klanova M, Friedberg J, Flowers C, Klener P, Maurer M, Habermann T, Trneny M, Cerhan J. Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma. Blood. 2025;146:2741.
• Vodicka P, El-Galaly TC, Prochazka V, Flowers C, Villa D, Dietrich C, Ghesquieres H, Clausen MR, Kridel R, Cheah C, Hawkes E, Wahlin B, Gandhi M, Larson M, Cahn E, Friedberg J, Martin P, Chihara D, Cohen J, Habermann T, Casulo C, Wang Y, Brown P, Mou E, Belada D, Janikova A, Mocikova H, Burack R, Lossos IS, Kahl B, Smedby KE, Sehn L, Trneny M, Cerhan J, Maurer M. Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation. Blood. 2025;146:3601.
• Hricko S, Klanova M, Vodicka P, Masar M, Blahovcova P, Dlouha J, Hajek M, Trneny M, Janikova A. Impact of primary CNS prophylaxis in high CNS-IPI DLBCL: Analysis from the czech national lymphoma registry. Blood. 2025;146:8019.
• Hamova I, Vodicka P, Velasova A, Kupcova K, Zemankova P, Nehasil P, Tkachenko A, Lochovska K, Muzikova S, Senavova J, Dlouha L, Klanova M, Sykorova A, Obr A, Benesova K, Suri A, Campr V, Galko J, Janikova A, Belada D, Prochazka V, Klener P, Mocikova H, Trneny M, Havranek O. Pre-treatment circulating tumor DNA predicts survival of diffuse large B-cell lymphoma patients and allows genetic and biological evaluation. Blood. 2025;146:1763.
• Alderuccio J, Vodička P, Koff J, Janikova A, Maurer M, Benesova K, Mocikova H, Martin P, Steinerova K, Patel D, Belada D, Cerhan J, Ďuraš J, Prochazka V, Cohen J, Salek D, Habermann T, Koren J, Larson M, Feldman A, Suri A, Reagan P, Sykorova A, Michalka J, Malarikova D, Wang Y, Jaye D, Prouzova Z, Blahovcova P, Campr V, Mou E, Flowers C, Lossos IS, Friedberg J, Nowakowski G, Chihara D, Trneny M. Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study. Blood. 2025;146:898.
• Falade A, Mwangi R, Okcu I, Ravindra A, Pradeep A, Hampel P, Zanwar S, Khan MA, Vodicka P, Klanova M, Masar M, Nedved A, Khurana A, Durani U, Paludo J, Andrade-Gonzalez X, Thanarajasingam G, Bennani NN, Thompson C, Hricko S, Janikova A, Wang Y, Johnston P, Ivana M, Novak A, King R, Maurer M, Witzig T, Ansell S, Mou E, Habermann T, Nowakowski G, Bisneto JV, Trneny M, Cerhan J, Abeykoon J. Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma. Blood. 2025;146:473.

EHA abstracts

• Vodicka P, Janikova A, Pytlik R, Polgarova K, Sykorova A, Folber F, Duras J, Steinerova K, Mocikova H, Prochazka V, Benesova K, Belada D, Kascak M, Sramek J, Benko F, Klener P, Dlouha J, Blahovcova P, Trneny M. Overall survival improvement of the R/R DLBCL patient population treated in the year 2021 and beyond. [abstract PF939]. HemaSphere. 2025;9(S1).
• Malarikova D, Kos IA, Janikova A, Belada D, Prochazka V, Benesova K, Blahovcova P, Thurner L, Trneny M, Poschel V. Four cycles of R-CHOP show the same effectivity as six cycles in real-world DLBCL patients with localized, non-bulky disease independently of other unfavourable risk factors. [abstract PS1936]. HemaSphere. 2025;9(S1).

ICML abstracts

• Mocikova H, Gaherova L, Jancarkova T, Suri A, Janikova A, Steinerova K, Belada D, Pytlik R, Duras J, Trnkova M, Blahovcova P, Kozak T, Trneny M. Assessing the efficacy and toxicity of cns prophylaxis in diffuse large b-cell lymphoma (clsg-cns-01): a randomized, multicenter, prospective phase 3 trial. [abstract 278]. Hematological Oncology. 2025;43:e278.
• Duras J, Vodicka P, Janikova A, Belada D, Prochazka V, Mocikova H, Lukac A, Steinerova K, Pirnos J, Brejcha M, Pukyova J, Benesova K, Salek D, Sykorova A, Obr A, Maco M, Hajek R, Hricko S, Blahovcova P, Dlouha J, Trneny M. Real world outcomes of the first-line treatment of localized extranodal marginal zone lymphoma of ocular adnexa or orbit. [abstract 590]. Hematological Oncology. 2025;43:e590.
• Belada D, Mocikova H, Obr A, Polgarova K, Steinerova K, Duras J, Stepankova P, Salek D, Jancakova T, Hanackova V, Trneny M. Safety and efficacy of glofitamab in relapsed/refractory diffuse large b cell lymphoma - data from real-world study. [abstract 647]. Hematological Oncology. 2025;43:e647.